Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test [Yahoo! Finance]
Castle Biosciences, Inc. - Common stock (CSTL)
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
See our latest analysis for Castle Biosciences. The endorsement appears to be feeding into a powerful upswing, with Castle Biosciences' share price delivering an 80.35% 3 month share price return and a 33.81% 1 year total shareholder return from a long term base that is still recovering. If this kind of clinical momentum has your attention, it could also be a smart time to explore other innovative healthcare names, using our healthcare stocks as a starting point. With the shares now hovering almost exactly at analyst target levels, but still trading at a hefty discount to some intrinsic value estimates, investors face a key question: Is Castle Biosciences still mispriced, or is future growth already fully reflected? Compared with the most popular narrative's fair value, Castle Biosciences' latest close of $38.63 implies a modest premium that hinges on ambitious long term assumptions. The analysts have a consensus price target of $35.625 for Castle Biosciences based on their
Show less
Read more
Impact Snapshot
Event Time:
CSTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSTL alerts
High impacting Castle Biosciences, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CSTL
News
- Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at BTIG Research from $38.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer [Yahoo! Finance]Yahoo! Finance
- Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal CancerGlobeNewswire
- Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with MelanomaGlobeNewswire
- Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? [Yahoo! Finance]Yahoo! Finance
CSTL
Earnings
- 11/3/25 - Beat
CSTL
Sec Filings
- 12/15/25 - Form 144
- 12/15/25 - Form 4
- 12/15/25 - Form 4
- CSTL's page on the SEC website